

NASH-TAG Conference

January 5, 2018

Mediators of Insulin Resistance and Organ Cross Talk

Gerald I. Shulman, M.D., Ph.D.
**Departments of Internal Medicine and
Cellular & Molecular Physiology
Howard Hughes Medical Institute
Yale University School of Medicine**

Disclosures

Scientific Advisory Boards: Merck, NovoNordisk, AstraZeneca,
Janssen Research and Development

Investigator Initiated Support: HHMI, NIH, Gilead Sciences, Celgene

A grim prediction :

By the year:

2050


1:3

Americans will have T2D

Complications of Diabetes



**Proliferative
Diabetic
Retinopathy**



**Diabetic
Nephropathy**



**Diabetic
Foot
Gangrene**

Global Projections for the Diabetes Epidemic: 2013-2035 (millions)

North America

37 M

South and Central America

24 M

Africa

20 M

35 M

Europe

56 M

Mid-East

72 M

Asia

138 M


WORLD

2013 = 382 million


2035 = 592 million

Increase 55%


Pathogenesis of Hyperglycemia in Type 2 Diabetes




^{13}C NMR Spectra of Muscle Glycogen




Incremental Change in Muscle Glycogen




Potential Rate-Controlling Steps in Muscle Glucose Metabolism




^{31}P NMR Spectra of Human Muscle





^{13}C NMR Spectra of Muscle and Plasma



Glucose Transport Activity Is Decreased in Type 2 Diabetes




^1H spectrum of the soleus muscle of a lean subject





Diacylglycerol (DAG)/PKC θ hypothesis of lipid-induced muscle insulin resistance

B




Insulin Sensitivity Index (n=~400)






Insulin Resistant


Insulin Resistant Single-Bout of Exercise



Diacylglycerol (DAG)-PKC ϵ Hypothesis of NAFLD-Induced Hepatic Insulin Resistance



Incubation of INSR with PKC ϵ reveals a novel threonine phosphorylation site




Thr¹¹⁶⁰ is conserved to *Drosophila*


| Species | Gene | Sequence |
|--------------------------------|--------------|------------|
| <i>Homo sapiens</i> | <i>Insr</i> | DIYETDYYRK |
| <i>Mus musculus</i> | <i>Insr</i> | DIYETDYYRK |
| <i>Xenopus laevis</i> | <i>insr</i> | DIYETDYYRK |
| <i>Danio rerio</i> | <i>insra</i> | DIYETDYYRK |
| <i>Drosophila melanogaster</i> | <i>InR</i> | DIYETDYYRK |
| <i>Caenorhabditis elegans</i> | <i>daf-2</i> | DLFYHDYYKP |

Thr¹¹⁶⁰ phosphorylation is predicted to destabilize the active configuration of the Insulin Receptor

Inactive




Active




Stevan Hubbard

IRK T1160E is kinase dead




IRK T1160A is protected from PKC ϵ inhibition





Insr^{T1150A} mice


Insr^{WT}/*Insr*^{WT}




Insr^{T1150A}/*Insr*^{T1150A}



Insr^{T1150A} mice are protected from high-fat diet induced hepatic insulin resistance



Working model: PKC ϵ Inhibition of Insulin Receptor Tyrosine Kinase Activity




Petersen et al. J Clin Invest 2016, Perry et al. Cell (published on line 1/5/18)

But.. is this relevant to humans?

Many studies great news for mice, not so much for humans


By **Elizabeth Landau**, CNN

June 8, 2010 8:18 a.m. EDT




Some study results in rodents are more applicable to humans than others.

Hepatic Diacylglycerol and PKC ϵ Activation Correlate with Insulin Resistance in Humans







Muscle Glucose Uptake (nmol/g/min)




% Suppression of Basal Hepatic Glucose Production



Muscle Fatty Acyl CoA (nmol/g)




Liver Fatty Acyl CoA (nmol/g)







Muscle Glucose Uptake (nmol/g/min)




% Suppression of Basal Hepatic Glucose Production



Muscle Fatty Acyl CoA (nmol/g)




Liver Fatty Acyl CoA (nmol/g)





Lipodystrophy Syndromes


- ◆ Paucity of fat
- ◆ Insulin resistance
- ◆ Hypertriglyceridemia
- ◆ Fatty infiltration of liver and other tissues
- ◆ Deficiency of adipocyte hormones (e.g. leptin)




Insulin Action: Control vs Lipodystrophy





Fasting Plasma Glucose Concentrations





Effect of Leptin on Insulin Action




^1H MRS Spectrum of Liver



Effect of Leptin on Tissue Triglyceride




Effect of Leptin on Energy Balance



Effect of Leptin Treatment in Lipodystrophy

Before Leptin




1 year on Leptin




Effects of Weight Loss in Obese Type 2 Diabetics


Fasting Plasma Glucose Before and After Wt Loss




Body Weight Before and After Diet




Hepatic Lipid Content




Rates of Glucose Production




Insulin Suppression of Glucose Production



How Insulin Works




Canonical insulin signaling of hepatic glucose metabolism




DIRECT Effects of Insulin to Stimulate Glycogen Synthesis

INDIRECT Effects of Insulin on Lipolysis to Inhibit Gluconeogenesis




Mechanisms by which Increased Lipolysis Inhibits Hepatic Glycogen Synthesis and Increases Hepatic Gluconeogenesis in T2D




Perry et al. Cell 2015
 Samuel et al., J Clin Invest 2016
 Petersen, Nature Endo Reviews 2017

Mechanism by Which a Very Low Calorie Diet Reverses Diabetes



Cellular Mechanisms of Insulin Resistance



Cell Metabolism

Perspective

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

Varman T. Samuel^{1,4,*} and Gerald I. Shulman^{1,2,3,*}

¹Department of Medicine

²Department of Cellular and Molecular Physiology

³Howard Hughes Medical Institute

Yale University School of Medicine, New Haven, CT 06510, USA

⁴Veterans Affairs Medical Center, West Haven, CT 06516, USA

*Correspondence: varman.samuel@yale.edu (V.T.S.), gerald.shulman@yale.edu (G.I.S.)

<http://dx.doi.org/10.1016/j.cmet.2017.08.002>

Cell Metabolism – published on line August 31, 2017

Reversal of Hypertriglyceridemia, Fatty Liver Disease, and Insulin Resistance by a Liver-Targeted Mitochondrial Uncoupler

Rachel J. Perry,^{1,2,3} Taehan Kim,⁴ Xian-Man Zhang,¹ Hui-Young Lee,^{1,3} Dominik Pesta,¹ Violeta B. Popov,²
Dongyan Zhang,¹ Yasmeen Rahimi,¹ Michael J. Jurczak,² Gary W. Cline,¹ David A. Spiegel,^{4,5} and Gerald I. Shulman^{1,2,3,6,*}

¹Howard Hughes Medical Institute

²Department of Internal Medicine

³Department of Cellular & Molecular Physiology

⁴Department of Pharmacology

Yale University School of Medicine, New Haven, CT 06519, USA

⁵Department of Chemistry, Yale University, New Haven, CT 06520, USA

⁶The Novo Nordisk Foundation Center for Basic Metabolic Research, 2200 Copenhagen N, Denmark

*Correspondence: gerald.shulman@yale.edu

<http://dx.doi.org/10.1016/j.cmet.2013.10.004>

Cell Metabolism 2013


METABOLIC DISEASE

Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats


Rachel J. Perry,^{1,2,3} Dongyan Zhang,¹ Xian-Man Zhang,²
James L. Boyer,^{2,4} Gerald I. Shulman^{1,2,3,*}

Science 2015

Mechanisms by which Increased Lipolysis Inhibits Hepatic Glycogen Synthesis and Increases Hepatic Gluconeogenesis



Liver-Targeted Mitochondrial Uncoupling



Collaborators

Abudukadier Abulizi

Gina Butrico

Rebecca Cardone

Gregori Casals

Gary Cline

Jinying Dong

Sylvie Dufour

Brandon Gassaway

Leigh Goedeke

Anne Impellizeri

Mario Kahn

Dick Kibbey

Xiruo Li

Kun Lyu

Yuichi Nozaki

Mikal Pallo

Rachel Perry

Max Petersen

Kitt Petersen

Gianluca Perseghin

Yang Qui

Jesse Rinehart

Rasmus Robøl

Michael Roden

Varman Samuel

Irina Smolgosky

Daniel Vatner

Zhang Ye

Dong Zhang

Xian-man Zhang

Yale-Mouse Metabolic Phenotyping Center

Joao Paulo Camporez

Ali Nasari

Yale-Magnetic Resonance Research Center

Douglas Befroy

Graeme Mason

Douglas Rothman

Robert Shulman

New York University

Steven Hubbard

NIH

Elif Arioglu Oral

Oksana Gavrilova

Philip Gorden

Marc Reitman

Simeon Taylor